Sarepta Therapeutics | SRPT - Current Liabilities


Sarepta Therapeutics reported $656.35M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Capricor Therapeutics USD 29.9M 3.07M Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Moderna USD 2.03B 506M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Novavax USD 329.84M 729K Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 29.77B 2.16B Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026